Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.
作者： Emanuela Scarpi , Marco Montanari , Giovanni Luca Frassineti , Wainer Zoli , Dino Amadori
DOI: 10.1700/1217.13491
关键词: Prednisone 、 Doxorubicin 、 Carcinoma 、 Prostate-specific antigen 、 Medicine 、 Chemotherapy 、 Orchiectomy 、 Internal medicine 、 Prostate cancer 、 Testosterone 、 Oncology
摘要: Aims and backgroundNon-pegylated liposomal doxorubicin (NPLD) (Myocet) has shown marked in vitro activity castration-resistant prostate cancer (CRPC) also docetaxel-resistant cells, highe...
elsevier.com
sagepub.com
istitutotumori.mi.it 参考文章(25)
Franco Paolorossi, Sergio Crispino, Gabriele Tancini, Sandro Barni, Caterina Archili, Paolo Lissoni, A weekly schedule of epirubicin in pretreated advanced breast cancer. Tumori. ,vol. 79, pp. 45- 48 ,(1993) , 10.1177/030089169307900110
Dario Nicolella, Giuseppe Grimaldi, Giuseppe Colantuoni, Mario Belli, Giuseppe Frasci, John Perchard, Pasquale Comelia, Weekly Low Dose Epirubicin in Elderly Cancer Patients Tumori. ,vol. 82, pp. 369- 371 ,(1996) , 10.1177/030089169608200414
Ronald G. Schwartz, William B. McKenzie, Jonathan Alexander, Philip Sager, Anthony D'Souza, Amita Manatunga, Peter E. Schwartz, Harvey J. Berger, John Setaro, Lee Surkin, Frans J.Th. Wackers, Barry L. Zaret, Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy The American Journal of Medicine. ,vol. 82, pp. 1109- 1118 ,(1987) , 10.1016/0002-9343(87)90212-9
Gerald Batist, Gopal Ramakrishnan, Chandra Sekhar Rao, Aruna Chandrasekharan, John Gutheil, Troy Guthrie, Pankaj Shah, Ali Khojasteh, Madhavan Krishnan Nair, Karen Hoelzer, Katherine Tkaczuk, Youn Choi Park, Lily W. Lee, Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 19, pp. 1444- 1454 ,(2001) , 10.1200/JCO.2001.19.5.1444
D. W. W. Newling, The use of adriamycin and its derivatives in the treatment of prostatic cancer. Cancer Chemotherapy and Pharmacology. ,vol. 30, ,(1992) , 10.1007/BF00686951
J.A.E. Balazsovits, L.D. Mayer, M.B. Bally, P.R. Cullis, M. McDonell, R.S. Ginsberg, R.E. Falk, Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin Cancer Chemotherapy and Pharmacology. ,vol. 23, pp. 81- 86 ,(1989) , 10.1007/BF00273522
Lodovico Balducci, Martine Extermann, Cancer chemotherapy in the older patient : What the medical oncologist needs to know Cancer. ,vol. 80, pp. 1317- 1322 ,(1997) , 10.1002/(SICI)1097-0142(19971001)80:7<1317::AID-CNCR18>3.0.CO;2-A
D.D. Lasic, F.J. Martin, A. Gabizon, S.K. Huang, D. Papahadjopoulos, Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times Biochimica et Biophysica Acta. ,vol. 1070, pp. 187- 192 ,(1991) , 10.1016/0005-2736(91)90162-2
Francesco Fabbri, Giovanni Brigliadori, Silvia Carloni, Paola Ulivi, Anna Tesei, Rosella Silvestrini, Dino Amadori, Wainer Zoli, Docetaxel–ST1481 sequence exerts a potent cytotoxic activity on hormone‐resistant prostate cancer cells by reducing drug resistance‐related gene expression The Prostate. ,vol. 70, pp. 219- 227 ,(2010) , 10.1002/PROS.21055
Christina Rangel, Haim Matzkin, Mark S. Soloway, Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer Urology. ,vol. 39, pp. 577- 582 ,(1992) , 10.1016/0090-4295(92)90023-P